NCT06383572 is a Phase 1, PHASE2 clinical trial of Cyclophosphamide in Lymphodepleting Chemotherapy, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT06383572?

NCT06383572 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT06383572?

Interventions in NCT06383572: Cyclophosphamide, Fludarabine phosphate, Decitabine, Dexamethasone.

What condition does NCT06383572 study?

NCT06383572 studies Lymphodepleting Chemotherapy, Myeloid Malignancies.

Is NCT06383572 still recruiting?

NCT06383572 is currently recruiting now. Last updated 23 December 2025.

Last reviewed 2025-12-23 · How we verify

NCT06383572

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Recruiting now Phase 1, PHASE2 Last updated 23 December 2025

What this trial tests

Phase 1, PHASE2 trial testing Cyclophosphamide in Lymphodepleting Chemotherapy in 44 participants. Currently enrolling.

Timeline

26 June 2024

Primary endpoint
1 April 2027

1 April 2029

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	26 June 2024
Primary completion	1 April 2027
Estimated completion	1 April 2029
Sites	1 location across United States

Drugs / interventions tested

Cyclophosphamide (cyclophosphamide) — full drug profile →
Fludarabine phosphate (FLUDARABINE PHOSPHATE) — full drug profile →
Decitabine (decitabine) — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Lymphodepleting Chemotherapy — all drugs for Lymphodepleting Chemotherapy →
Myeloid Malignancies — all drugs for Myeloid Malignancies →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 18 to 80, any sex, with Lymphodepleting Chemotherapy or Myeloid Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.
Chen S, Zhu H, Jounaidi Y. · · 2024 · cited 106× · PMID 39511139 · DOI 10.1038/s41392-024-02005-w
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.
Song J, Yang P, Chen C, Ding W, et al · · 2025 · cited 40× · PMID 40675967 · DOI 10.1038/s41392-025-02266-z

Verify or expand the search:

Other trials of Cyclophosphamide

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07509008 — Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Manageme · Phase 1, PHASE2 · not yet recruiting
NCT07444632 — Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/ · Phase 1 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07437963 — Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen · Phase 1, PHASE2 · not yet recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06383572 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 23 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06383572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing